PMID- 11528574
OWN - NLM
STAT- MEDLINE
DCOM- 20011204
LR  - 20220317
IS  - 1058-4838 (Print)
IS  - 1058-4838 (Linking)
VI  - 33
IP  - 7
DP  - 2001 Oct 1
TI  - Atovaquone-proguanil versus mefloquine for malaria prophylaxis in nonimmune 
      travelers: results from a randomized, double-blind study.
PG  - 1015-21
AB  - Concerns about the tolerability of mefloquine highlight the need for new drugs to 
      prevent malaria. Atovaquone-proguanil (Malarone; GlaxoSmithKline) was safe and 
      effective for prevention of falciparum malaria in lifelong residents of 
      malaria-endemic countries, but experience in nonimmune people is limited. In a 
      randomized, double-blind study, nonimmune travelers received malaria prophylaxis 
      with atovaquone-proguanil (493 subjects) or mefloquine (483 subjects). 
      Information about adverse events (AEs) and potential episodes of malaria was 
      obtained 7, 28, and 60 days after travel. AEs were reported by an equivalent 
      proportion of subjects who had received atovaquone-proguanil or mefloquine (71.4% 
      versus 67.3%; difference, 4.1%; 95% confidence interval, -1.71 to 9.9). Subjects 
      who received atovaquone-proguanil had fewer treatment-related neuropsychiatric 
      AEs (14% versus 29%; P=.001), fewer AEs of moderate or severe intensity (10% 
      versus 19%; P=.001), and fewer AEs that caused prophylaxis to be discontinued 
      (1.2% versus 5.0%; P=.001), compared with subjects who received melfoquine. No 
      confirmed diagnoses of malaria occurred in either group. Atovaquone-proguanil was 
      better tolerated than was mefloquine, and it was similarly effective for malaria 
      prophylaxis in nonimmune travelers.
FAU - Overbosch, D
AU  - Overbosch D
AD  - Harbor Hospital and Institute of Tropical Medicine, Rotterdam, The Netherlands.
FAU - Schilthuis, H
AU  - Schilthuis H
FAU - Bienzle, U
AU  - Bienzle U
FAU - Behrens, R H
AU  - Behrens RH
FAU - Kain, K C
AU  - Kain KC
FAU - Clarke, P D
AU  - Clarke PD
FAU - Toovey, S
AU  - Toovey S
FAU - Knobloch, J
AU  - Knobloch J
FAU - Nothdurft, H D
AU  - Nothdurft HD
FAU - Shaw, D
AU  - Shaw D
FAU - Roskell, N S
AU  - Roskell NS
FAU - Chulay, J D
AU  - Chulay JD
CN  - Malarone International Study Team
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
DEP - 20010905
PL  - United States
TA  - Clin Infect Dis
JT  - Clinical infectious diseases : an official publication of the Infectious Diseases 
      Society of America
JID - 9203213
RN  - 0 (Antimalarials)
RN  - 0 (Drug Combinations)
RN  - 0 (Naphthoquinones)
RN  - S61K3P7B2V (Proguanil)
RN  - TML814419R (Mefloquine)
RN  - Y883P1Z2LT (Atovaquone)
SB  - IM
CIN - Clin Infect Dis. 2002 May 1;34(9):1278; author reply 1278-9. doi: 10.1086/339761. 
      PMID: 11941558
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Antimalarials/administration & dosage/adverse effects/*therapeutic use
MH  - Atovaquone
MH  - Child
MH  - Child, Preschool
MH  - Double-Blind Method
MH  - Drug Combinations
MH  - Female
MH  - Humans
MH  - Malaria/immunology/*prevention & control
MH  - Male
MH  - Mefloquine/administration & dosage/adverse effects/*therapeutic use
MH  - Middle Aged
MH  - Naphthoquinones/administration & dosage/adverse effects/*therapeutic use
MH  - Proguanil/administration & dosage/adverse effects/*therapeutic use
MH  - *Travel
MH  - Treatment Outcome
EDAT- 2001/08/31 10:00
MHDA- 2002/01/05 10:01
CRDT- 2001/08/31 10:00
PHST- 2001/01/24 00:00 [received]
PHST- 2001/03/27 00:00 [revised]
PHST- 2001/08/31 10:00 [pubmed]
PHST- 2002/01/05 10:01 [medline]
PHST- 2001/08/31 10:00 [entrez]
AID - CID010125 [pii]
AID - 10.1086/322694 [doi]
PST - ppublish
SO  - Clin Infect Dis. 2001 Oct 1;33(7):1015-21. doi: 10.1086/322694. Epub 2001 Sep 5.